Almirall Extends Dermatology Reach With Dermira Lebrikizumab Deal
Executive Summary
Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.
You may also be interested in...
Busy 2021 Ahead For Almirall On Business And Clinical Fronts
Gianfranco Nazzi will be taking over as head of the Spanish company shortly and the Barcelona-based firm's prospects look good as its dermatology portfolio and pipeline blossom.
Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab
Making a large acquisition heading into the JP Morgan Healthcare Conference for the second consecutive year, Lilly is buying Dermira and its Phase III atopic dermatitis drug lebrikizumab, setting up a competition with Sanofi’s Dupixent.
No Alarm At Almirall Despite Stake Sale
Shares in the Spanish dermatology specialist have slipped as the majority shareholder sold a 6.3% stake. However, sales of its psoriasis and acne drugs, plus some promising late-stage assets, suggest Almirall is in rude health.